Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.60 |
| ▸ | DRD2 | P14416 | 5/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | HTR1D | P28221 | 4/20 | 0.51 |
| ▸ | HTR1B | P28222 | 4/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2303617 | 0.87 | HTR1A (0.52) | HTR1ADRD2HTR2ASLC6A4HTR1D | |
| SCHEMBL531687 | 0.82 | DRD2 (0.66) | HTR1ADRD2HTR2ASLC6A4HTR1D | |
| SCHEMBL22491520 | 0.80 | MGLL (0.57) | HTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL29734499 | 0.80 | MGLL (0.57) | HTR1AHTR1DHTR1BNR3C2 | |
| SCHEMBL7529023 | 0.77 | HTR1A (0.64) | HTR1ADRD2HTR2ASLC6A4HTR7 | |
| SCHEMBL532718 | 0.77 | PARP1 (0.80) | HTR1ADRD2HTR2ASLC6A4HTR1D | |
| Hydrochloric Acid SCHEMBL9030489 | 0.76 | HTR1A (0.63) | HTR1ADRD2HTR2ASLC6A4HTR7 | |
| SCHEMBL532067 | 0.75 | DRD2 (0.66) | HTR1ADRD2HTR2ASLC6A4HTR1D | |
| Hydrochloric Acid SCHEMBL9048212 | 0.75 | OPRM1 (0.57) | HTR1ADRD2HTR2ASLC6A4HTR1D | |
| SCHEMBL532657 | 0.75 | DRD2 (0.81) | HTR1ADRD2HTR2ASLC6A4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | claimed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | HTR1A 47/4885DRD2 251/4885HTR2A 87/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | HTR1A 476/4885DRD2 574/4885HTR2A 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.